调整T细胞受体亲和力以优化靶向甲胎蛋白阳性肝癌的临床风险-获益
肝细胞癌(HCC)预后差、治疗选择有限,甲胎蛋白(AFP)在HCC中常高表达且为非恶性肝组织低表达,是免疫治疗有希望的靶点。研究通过数据库检索、qPCR和免疫组化验证AFP在正常、病变和恶性肝组织的表达,并用体外诱变和筛选生成识别HLA-A*02限制性AFP158-166肽段FMNKFIYEI的亲和力优化T细胞受体(TCR),经丙氨酸扫描扩展(X-扫描)及针对多种组织、细胞类型和HLA等位基因的正常与肿瘤细胞测试确认其效力和特异性平衡。结论认为该TCR转导T细胞有望区分非恶性与癌细胞上的抗原水平,构成HCC过继T细胞免疫治疗试验的基础。
要点
- AFP在HCC中常高表达,在非恶性肝组织(尤其部分祖细胞和慢性炎症时)通常低表达,是免疫治疗有希望的靶点。
- 研究生成识别HLA-A*02限制性AFP158-166肽段FMNKFIYEI的亲和力优化TCR,具有效力和特异性的最佳平衡。
- 该TCR转导T细胞构成HCC过继T细胞免疫治疗试验的基础。
核心结论
- 研究结合物理化学、计算机模拟和细胞生物学方法优化TCR的亲和力和功能,其特性预期可使TCR转导T细胞区分非恶性细胞与癌细胞上的抗原水平,构成HCC过继T细胞免疫治疗试验的基础。
研究设计与样本
- 研究通过数据库检索、qPCR和免疫组化分析一组人类组织样本(包括正常、病变和恶性肝组织)验证AFP表达,并用体外诱变和筛选生成TCR。
主要发现
- AFP在HCC中常高表达,在非恶性肝组织尤其部分祖细胞和慢性炎症时也可表达,但水平通常低于HCC。
- 生成的TCR识别HLA-A*02限制性AFP158-166肽段FMNKFIYEI,具有效力和特异性的最佳平衡,经X-扫描及针对多种组织、细胞类型和HLA等位基因的正常与肿瘤细胞测试确认。
关键数值与推荐
- TCR识别HLA-A*02限制性AFP158-166肽段,序列为FMNKFIYEI。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with hepatocellular carcinoma (HCC) have a poor prognosis and limited therapeutic options. Alpha-fetoprotein (AFP) is often expressed at high levels in HCC and is an established clinical biomarker of the disease. Expression of AFP in nonmalignant liver can occur, particularly in a subset of progenitor cells and during chronic inflammation, at levels typically lower than in HCC. This cancer-specific overexpression indicates that AFP may be a promising target for immunotherapy. We verified expression of AFP in normal and diseased tissue and generated an affinity-optimized T-cell receptor (TCR) with specificity to AFP/HLA-A*02+ tumors. Expression of AFP was investigated using database searches, by qPCR, and by immunohistochemistry (IHC) analysis of a panel of human tissue samples, including normal, diseased, and malignant liver. Using in vitro mutagenesis and screening, we generated a TCR that recognizes the HLA-A*02-restricted AFP158-166 peptide, FMNKFIYEI, with an optimum balance of potency and specificity. These properties were confirmed by an extension of the alanine scan (X-scan) and testing TCR-transduced T cells against normal and tumor cells covering a variety of tissues, cell types, and human leukocyte antigen (HLA) alleles. Conclusion: We have used a combination of physicochemical, in silico, and cell biology methods for optimizing a TCR for improved affinity and function, with properties that are expected to allow TCR-transduced T cells to differentiate between antigen levels on nonmalignant and cancer cells. T cells transduced with this TCR constitute the basis for a trial of HCC adoptive T-cell immunotherapy.
引用
- Docta RY, Ferronha T, Sanderson JP, et al. Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer. Hepatology. 2019. PMID: 30561769. doi:10.1002/hep.30477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。